title: The mGluR2/3 agonist LY379268 reverses post-weaning social isolation-induced recognition memory deficits in the rat.
abstract: BACKGROUND
  Current antipsychotics are ineffective at treating the negative and cognitive symptoms of schizophrenia, so there is a substantial need to develop more effective therapeutics for this debilitating disorder. The type II metabotropic glutamate receptor (mGluR2/3) is a novel, potential therapeutic target requiring evaluation in appropriate preclinical models of schizophrenia.
  
  
  OBJECTIVE
  This study evaluated the potent, selective mGluR2/3 agonist, LY379268, on the behavioural deficits induced by rearing rat pups in social isolation from weaning, a neurodevelopmental model of schizophrenia, to investigate its antipsychotic potential.
  
  
  METHODS
  Male Lister Hooded rats were weaned on post-natal day 23-25 and either group-housed (3-4 per cage) or isolation-reared for 6 weeks. At subsequent weekly intervals, animals received acute systemic injection of either vehicle or LY379268 (1 mg/kg; i.p.) 30 min prior to recording locomotor activity in a novel arena, novel object recognition, pre-pulse inhibition of acoustic startle and conditioned emotional response paradigms.
  
  
  RESULTS
  Isolation rearing induced locomotor hyperactivity, deficits in novel object recognition, conditioned emotional behaviour and attenuated the magnitude of the initial acoustic startle response in the PPI paradigm compared to that of group-housed controls. LY379268 reversed the isolation-induced locomotor hyperactivity, the object recognition deficit, and restored startle responses in isolated animals, whilst having no effect on conditioned emotional response impairments.
  
  
  CONCLUSIONS
  These data show that LY379268 can reverse some, but not all, post-weaning social isolation-induced changes which have translational relevance to core symptom defects in schizophrenia and support a potential therapeutic role of mGluR2/3 agonists in its treatment.
authors.affiliation: School of Biomedical Sciences, Queen's Medical Centre, University of Nottingham, Nottingham, NG7 2UH, UK.
authors.forename: Caitlin A
authors.initials: CA
authors.lastname: Jones
authors.forename: Angus M
authors.initials: AM
authors.lastname: Brown
authors.forename: Dorothee P
authors.initials: DP
authors.lastname: Auer
authors.forename: Kevin C F
authors.initials: KC
authors.lastname: Fone
mesh_terms: D000596:Amino Acids / Q000494:pharmacology*; D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology*; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000494:pharmacology*; D004195:Disease Models, Animal; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D051381:Rats; D018094:Receptors, Metabotropic Glutamate / Q000819:agonists*; D021641:Recognition, Psychology / Q000187:drug effects; D013216:Reflex, Startle / Q000187:drug effects; D012559:Schizophrenia / Q000188:drug therapy / Q000503:physiopathology; D012934:Social Isolation
chemical_list: D000596:Amino Acids; D014150:Antipsychotic Agents; D019086:Bridged Bicyclo Compounds, Heterocyclic; C118218:LY 379268; D018094:Receptors, Metabotropic Glutamate; C108822:metabotropic glutamate receptor 2; C102718:metabotropic glutamate receptor 3